Company intelligence / Profile preview

Jiangsu T-mab Biopharma Co., Ltd.

Taizhou, Jiangsu Province, Chinat-mab.com ↗

Ownership: Private
Development stage: Other

Overview

The company has successfully developed and commercialized several products, including a denosumab biosimilar that received approval in China in March 2023 for postmenopausal osteoporosis and in March 2024 for Giant Cell Tumor of Bone. Their albipagrastim alfa (targeting CSF-3R) has reached NDA/BLA stage, and their anti-VEGF humanized monoclonal antibody is in Phase 3 for wet age-related macular degeneration.

Therapeutic areas: OncologyOphthalmologyEndocrinologyImmunologyHematology
Modalities: Monoclonal antibodiesFusion proteinsRecombinant protein drugsBiosimilars
Industry: Biotech

Partnerships

School of Pharmacy at Shanghai Jiao Tong University (SJTU)Taizhou Medical New&Hi-tech Industrial Development Zone

Beyond the preview

Go deeper on Jiangsu T-mab Biopharma Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jiangsu T-mab Biopharma Co., Ltd..